Instrument Inactif

Communiqués Enzymatica AB Nasdaq Stockholm

Actions

SE0003943620

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Interim results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days	13/06	AQ
Bulletin from annual general meeting of Enzymatica AB (publ) on May 7, 2024	07/05	AQ
BioStock: MDR certification was Enzymatica's highlight in Q1	29/04	AQ
Enzymatica Q1 - Continued growth in own markets, but a lack of partner orders	26/04	AQ
Interim report Q1/2024: MDR certification opens up great commercial opportunities	25/04	AQ
Enzymatica publishes annual report for 2023	09/04	AQ
Notice of Annual General Meeting 2024 in Enzymatica AB (publ)	27/03	AQ
BioStock: Enzymatica comments on MDR certification for ColdZyme	20/03	AQ
Enzymatica announces outcome of new rights issue	14/03	AQ
ColdZyme® certified under the new EU medical device regulation (MDR)	11/03	AQ
BioStock: Enzymatica's partners await MDR certification and study results	26/02	AQ
Enzymatica publishes information memorandum about rights issue of shares	19/02	AQ
Enzymatica Q4 - Important year ahead and an expected rights issue	19/02	AQ
Enzymatica's rights issue is secured to 100 percent	16/02	AQ
Year-end report 2023: Scientific and regulatory progress generating international interest	16/02	AQ
Enzymatica's Board of Directors decides on a new rights issue of SEK 27.4 million	16/02	AQ
Enzymatica's Chairman to BioStock: "Our new research data makes 2024 an exciting year"	21/12	AQ
Enzymatica changes Certified Adviser to Carnegie Investment Bank AB (publ)	30/11	AQ
BioStock: Enzymatica focuses on strengthening the distributor level	08/11	AQ
Enzymatica Q3 - The STADA partnership creating concerns about the future	08/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Enzymatica AB Nasdaq Stockholm

Actions

SE0003943620

Communiqués

Filtres